Kristen Nieves
Adult Health · Miami, FLNPI 1063840379
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 792 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 792 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Madrigal Pharmaceuticals$2K
- Johnson & Johnson$1K
- Intercept Pharmaceuticals, Inc.$1K
- Ardelyx, Inc.$807
- plus $5K from 25 others
What the payments were for
- Consulting fees$1,0807%
- Speaking & faculty fees$150%
- Travel & lodging$90%
- Food & beverage$14,15291%
- Education$2622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 149 | $3,055 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 200 | $2,616 |
| Madrigal Pharmaceuticals | 22 | $1,583 |
| Johnson & Johnson(2 entities) | 74 | $1,366 |
| Intercept Pharmaceuticals, Inc. | 50 | $1,262 |
| Ardelyx, Inc. | 53 | $807 |
| Ipsen Biopharmaceuticals, Inc | 30 | $729 |
| Redhill Biopharma Inc. | 71 | $679 |
| Gilead | 27 | $611 |
| Phathom Pharmaceuticals, Inc. | 21 | $529 |
| Aimmune Therapeutics, Inc. | 8 | $337 |
| Janssen Scientific Affairs, LLC | 3 | $276 |
| E.r. Squibb & Sons, L.L.C. | 3 | $271 |
| Vivus LLC | 13 | $222 |
| Bristol Myers Squibb | 12 | $201 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $183 |
| Nestle Healthcare Nutrition Inc. | 14 | $181 |
| Lilly USA, LLC | 5 | $103 |
| Evoke Pharma, Inc. | 6 | $91 |
| Daiichi Sankyo Inc. | 4 | $79 |
| Braintree Laboratories, Inc. | 4 | $64 |
| Novo Nordisk | 2 | $50 |
| Ironwood Pharmaceuticals, Inc | 3 | $44 |
| Pfizer | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Alfasigma USA, Inc. | 2 | $28 |
| Medtronic | 1 | $17 |
| Merck | 1 | $16 |
| Napo Pharmaceuticals Inc | 1 | $15 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,518 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 106 | $381,543 |
| XifaxanRifaximin | 112 | $355,466 |
| ZenpepLipase/Protease/Amylase | 62 | $340,085 |
| StelaraUstekinumab | 11 | $300,612 |
| LinzessLinaclotide | 196 | $192,852 |
| Humira(Cf) PenAdalimumab | 18 | $183,118 |
| OcalivaObeticholic Acid | 12 | $111,312 |
| VemlidyTenofovir Alafenamide | 44 | $69,592 |
| RezdiffraResmetirom | 14 | $55,841 |
| IbsrelaTenapanor Hcl | 22 | $39,182 |
| TrulancePlecanatide | 36 | $27,291 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 137 | $23,349 |
| Dexlansoprazole DrDexlansoprazole | 53 | $19,921 |
| Ursodiol | 70 | $14,923 |
| Mesalamine | 35 | $13,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,055 | $574,396302 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $2,616 | $382,758148 claims |
| Aimmune Therapeutics, Inc.Zenpep | $337 | $340,08562 claims |
| Johnson & JohnsonStelara | $1,366 | $300,61211 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $1,262 | $111,31212 claims |
| GileadVemlidy | $611 | $69,59244 claims |
| Madrigal PharmaceuticalsRezdiffra | $1,583 | $55,84114 claims |
| Ardelyx, Inc.Ibsrela | $807 | $39,18222 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $529 | $9,45811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $183 | $7,82920 claims |
| Braintree Laboratories, Inc.Suflave | $64 | $4,56436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Miami
- Norma SolisMiami$150K
- Jeffrey HernandezMiami$122K
- Jose ChamorroMiami$15K
- Wendy KaysMiami$13K
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Ashley PontenbergWinter Park$136K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.